Impact of the PPAR-γ2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: Evidence from BENEDICT

Salvatore De Cosmo, Nicola Motterlini, Sabrina Prudente, Fabio Pellegrini, Roberto Trevisan, Antonio Bossi, Giuseppe Remuzzi, Vincenzo Trischitta, Piero Ruggenenti

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE - Cross-sectional studies found less microalbuminuria in type 2 diabetic patients with the Ala12 allele of the peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) Pro12Ala polymorphism. We prospectively evaluated the association between Pro12Ala polymorphism (rs1801282) and newonset microalbuminuria. RESEARCH DESIGN AND METHODS - Pro12Ala polymorphism was genotyped by TaqMan-based assay in genomic DNA of 1,119 consenting patients from BErgamo NEphrologic DIabetic Complications Trial (BENEDICT) - a prospective, randomized trial evaluating ACE inhibition effect on new-onset microalbuminuria (albuminuria 20-200 μg/min in at least two of three consecutive overnight urine collections in two consecutive visits) in hypertensive type 2 diabetes with albuminuria

Original languageEnglish
Pages (from-to)2920-2929
Number of pages10
JournalDiabetes
Volume58
Issue number12
DOIs
Publication statusPublished - Dec 2009

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Impact of the PPAR-γ2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: Evidence from BENEDICT'. Together they form a unique fingerprint.

Cite this